Cargando…

Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder

BACKGROUND: Older patients (> 65 yr) suffering from overactive bladder (OAB) are more likely to have functional impairment and comorbidity than those without OAB. This article reviews available published studies and discusses how fesoterodine might meet the specific needs of the older OAB patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heesakkers, John, te Dorsthorst, Manon, Wagg, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Canadian Geriatrics Society 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887709/ https://www.ncbi.nlm.nih.gov/pubmed/35310472 http://dx.doi.org/10.5770/cgj.25.530

Ejemplares similares

Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
por: Morris, Vikky, et al.
Publicado: (2014)

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
por: Heesakkers, John, et al.
Publicado: (2017)

Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome
por: te Dorsthorst, Manon, et al.
Publicado: (2021)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
por: Wyndaele, Jean-Jacques
Publicado: (2012)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2010)

Patient‐tailored healthcare and tibial nerve neuromodulation in the treatment of patients with overactive bladder symptoms
por: te Dorsthorst, Manon, et al.
Publicado: (2022)

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine
por: Wagg, Adrian S., et al.
Publicado: (2021)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

NGF and HB-EGF: Potential Biomarkers that Reflect the Effects of Fesoterodine in Patients with Overactive Bladder Syndrome
por: Kim, Soo Rim, et al.
Publicado: (2015)

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

Overactive bladder: strategies to ensure treatment compliance and adherence
por: Dhaliwal, Prabhpreet, et al.
Publicado: (2016)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain
por: Peral, Carmen, et al.
Publicado: (2016)

Do Older Adults with Overactive Bladder Demonstrate Impaired Executive Function Compared to Their Peers Without OAB?
por: Gibson, William, et al.
Publicado: (2020)

Urinary urgency acts as a source of divided attention leading to changes in gait in older adults with overactive bladder
por: Gibson, William, et al.
Publicado: (2021)

Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome
por: de Wall, Liesbeth L, et al.
Publicado: (2017)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Which drugs are best for overactive bladder? From patients’ expectations to physicians’ decisions
por: Milsom, Ian, et al.
Publicado: (2020)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
por: van Rey, Farida, et al.
Publicado: (2011)

Overactive Bladder: Pathophysiology, Diagnostics, and Therapies
por: Heesakkers, John P. F. A., et al.
Publicado: (2011)

Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder
por: Wagg, Adrian
Publicado: (2012)

Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients
por: te Dorsthorst, Manon J., et al.
Publicado: (2019)

The Association Between Overactive Bladder and Falls and Fractures: A Systematic Review
por: Szabo, Shelagh M., et al.
Publicado: (2018)

Clinical utility of neurostimulation devices in the treatment of overactive bladder: current perspectives
por: Janssen, Dick AW, et al.
Publicado: (2017)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
por: Javan Balegh Marand, Aida, et al.
Publicado: (2023)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
por: Herschorn, Sender, et al.
Publicado: (2020)

Treatment Patterns for Patients on Overactive Bladder Therapy: A Retrospective Statistical Analysis Using Canadian Claims Data
por: Wagg, Adrian, et al.
Publicado: (2016)

Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life
por: Jayarajan, Jyotsna, et al.
Publicado: (2013)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
por: Castro-Diaz, David, et al.
Publicado: (2012)

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature
por: Masumori, Naoya
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_eksjc23raq7f0e7jtt8t293b9e